03 Feb
2023
09:41 E.S.T.

Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information

Read more

02 Feb
2023
17:47 E.S.T.

Cellectis Announces Pricing of Follow-On Offering

Read more

02 Feb
2023
16:19 E.S.T.

Cellectis Announces Launch of Follow-On Offering

Read more

20 Jan
2023
16:30 E.S.T.

Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics

Read more

17 Jan
2023
07:10 E.S.T.

Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement

Read more

04 Jan
2023
17:00 E.S.T.

Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq

Read more

29 Dec
2022
16:30 E.S.T.

Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases

Read more

28 Dec
2022
12:59 E.S.T.

Cellectis secures a €40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities

Read more

22 Dec
2022
16:30 E.S.T.

Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL

Read more

13 Dec
2022
07:30 E.S.T.

Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML

Read more